← SynDRA
BALSALAZIDE
SynDRA canonical compound SYN0023549 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx/OTC |
|---|
| Primary target(s) | ALOX5 | PPARG | PTGS1 | PTGS2 |
|---|
| Mechanism of action | cyclooxygenase inhibitor |
|---|
| Indication | ulcerative colitis |
|---|
| Disease area | gastroenterology |
|---|
All known targets
- PTGS1
- ALOX5
- PPARG
- PTGS2
- SIRT5
- CHUK
- CTNNB1
- IKBKB
- MPO
- NAT1
- IFNG
- TPMT
Mechanisms of action (all sources)
- ALOX5 INHIBITOR
- PTGS2 INHIBITOR
- PTGS1 INHIBITOR
- PPARG AGONIST
- cyclooxygenase inhibitor
- Lipoxygenase inhibitor
- Prostanoid receptor antagonist
- Arachidonate 5-lipoxygenase inhibitor
- Peroxisome proliferator-activated receptor gamma agonist
- PPARG FULL AGONIST
- ABCG2 INHIBITOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- ACHE
- MAOA
- NPY1R
- NME4
- MMP9
- MMP1
- MLNR
- MC5R
- MC4R
- MC3R
- MAPK3
- MAPK14
- MAPK1
- LCK
- GCDH
- KCNH2
- HTR6
- HTR3A
- HTR2C
- HTR2B
- HTR2A
- HTR1A
- HRH3
- HRH2
- HRH1
- HMGCR
- NPY2R
- NR1I2
- NR3C1
- OPRD1
- TBXAS1
- TBXA2R
- TACR2
- TACR1
- SLC6A4
- SLC6A3
- SLC6A2
- SLC29A1
- SIRT3
- SIRT2
Drug classes
- Analgesics
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Antirheumatic Agents
- Gastrointestinal Agents
- Peripheral Nervous System Agents
- Sensory System Agents
- Aminosalicylate
- Anti-Infective Agents
ATC classes
- A07E · INTESTINAL ANTIINFLAMMATORY AGENTS
Cross-references
Synonyms
- balsalazide disodium
- balsalazide sodium
- Balsalazida
- Balsalazido
- Balsalazidum
- Colazal
- Balsalazida [Spanish]
- Balsalazide Disodium
- Balsalazido [Spanish]
- Balsalazidum [Latin]
- Balsalazide (INN)
- Balsalazide [INN:BAN]
- Colazal (TN)
- Colazide (TN)
- (3Z)-3-[[4-(2-carboxyethylcarbamoyl)phenyl]hydrazinylidene]-6-oxocyclohexa-1,4-diene-1-carboxylic acid
- (E)-5-((4-(((2-Carboxyethyl)amino)carbonyl)phenyl)azo)-2-hydroxybenzoic acid
- (E)-5-({p-[(2-carboxyethyl)carbamoyl]phenyl}azo)-2-salicylic acid
- 3-(2-{4-[(2-carboxyethyl)carbamoyl]phenyl}hydrazinylidene)-6-oxocyclohexa-1,4-diene-1-carboxylic acid
- 5-[(E)-{4-[(2-carboxyethyl)carbamoyl]phenyl}diazenyl]-2-hydroxybenzoic acid
- 5-[4-(2-carboxy-ethylcarbamoyl)-phenylazo]-2-hydroxy-benzoic acid
- (e)-5-((4-(((2-Carboxyethyl)amino)carbonyl)phenyl)azo)-2-hydroxybenzoic acid
- (e)-5-({p-[(2-carboxyethyl)carbamoyl]phenyl}azo)-2-salicylic acid
- 5-[4-(2-Carboxy-ethylcarbamoyl)-phenylazo]-2-hydroxy-benzoic acid
- بالسالازيد
- Balsalazid
- بالسالازید
- balsalazyd
Reported adverse events
- Rash
- Acne
- Back pain
- Nephrogenic diabetes insipidus
- Abdominal distension
- Hypertension
- Liver function test abnormal
- Pancreatitis
- Renal failure
- Investigation
- Asthenia
- Ear pain
Look up BALSALAZIDE in the interactive SynDRA portal →